Figure 1.

CNX-012-570 activates AMPK in multiple tissues in vitro and in vivo: (A) Kinetics of AMPK activation by CNX-012-570 (0.3 μM) as measured by p-AMPK protein levels in HepG2, C2C12 myotubes and 3T3L1 adipocytes. (B) AMPK activation (p-AMPK protein levels) and its downstream targets proteins phosphorylation (HNF4α, ACC and HSL) from liver, skeletal muscle and adipose tissue respectively from SAM mice after CNX-012-570 treatment (3 doses; 3 mg/kg, orally once a day). (C) At the end of the treatment period in both DIO and db/db mice, AMPK activation (p-AMPK protein levels) were measured. CNX-012-570 was dosed with 3 mg/kg and 2.5 mg/kg, orally once a day in DIO and db/db mice respectively. Blots were developed using specific primary antibodies and HRP conjugated secondary antibody using enhanced ECL reagent as mentioned in the Methods.

Anil et al. Cardiovascular Diabetology 2014 13:27   doi:10.1186/1475-2840-13-27
Download authors' original image